C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
Location: United States, New York
Employees: 11-50
Total raised: $112M
Founded date: 2019
Investors 4
| Date | Name | Website |
| - | LionBird | lionbird.c... |
| - | S32 | s32.com |
| 24.09.2020 | NFX | nfx.com |
| - | Endless Fr... | endlessfro... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.04.2021 | Series B | $100M | - |
| 10.06.2020 | Series A | $12M | - |
Mentions in press and media 12
| Date | Title | Description |
| 03.02.2023 | C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan | What You Should Know: – C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of n... |
| 15.04.2021 | C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform | – Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. – Funds will be used to accelerate clinical d... |
| 15.04.2021 | C2i Genomics, Inc. announced that it has received $100 million in funding from a group of investors | On April 15, 2021, C2i Genomics, Inc. closed the transaction. The company raised $50,000,000 in its second tranche closing, bringing the total gross proceeds raised in the transaction to $100,000,000. The transaction was led by returning in... |
| 15.04.2021 | C2i Genomics Raises $100M in Funding | C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing. The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. Th... |
| 15.04.2021 | C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B | If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so, will the doctors catch it at an early enou... |
| 10.06.2020 | C2i Genomics Closes $12 Million In Funding | C2i Genomics, a company that is focused on improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, announced it has raised $12 million C2i Genomics, a company that is focused on ... |
| 09.06.2020 | C2i Genomics raises $12M Series A funding to improve cancer patient lives and outcomes with breakthrough technology | C2i Genomics (“C2i”), a New York City-based biotech startup that offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA, today announced it has raised $12 million in... |
| 09.06.2020 | C2i Genomics Scoops Up $12M Series A | NEW YORK, NY, C2i Genomics has raised $12 million in a Series A financing round. >> Click here for more funding data on C2i Genomics >> To export C2i Genomics funding data to PDF and Excel, click here C2i Genomics ("... |
| 09.06.2020 | C2i Genomics Raises $12 Million in Series A Funding | NEW YORK--(BUSINESS WIRE)--C2i Genomics, a company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, today announced that it has raised $12 million in its Seri... |
| 09.06.2020 | C2i Genomics Raises $12M in Series A Funding | C2i Genomics, a NYC-based company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, raised $12m in Series A financing. The round was led by Casdin Capital and ... |
Show more